Sector News

Confusion over Europe’s chief scientific adviser post

January 20, 2015
Life sciences
A spokesperson from the European commission has confirmed that the chief scientific adviser post will not be reinstated, after remarks made by vice-president Frans Timmermans at a meeting caused confusion last week. Timmermans appeared to promise that the post will stay – contrary to President Jean-Claude Juncker’s widely condemned decision to scrap it – at a meeting of the European Conservatives & Reformists in Strasbourg on the 13 January.
 
But Juncker’s spokesperson Natasha Bertaud told Chemistry World that the commission’s position on this ‘has not changed’ and confirmed that the decision to axe the post still stands.
 
MEPs Vicky Ford and Ian Duncan publicised notes taken at the meeting, during which Ford apparently told Timmermans: ‘When Mr Juncker came to this group, he promised he would keep a chief scientific adviser. Please keep that promise.’ Timmermans responded that ‘the promise stands’ and added ‘we will have a chief scientific adviser, Right?’
 
The pair took this as an assurance the position would be reinstated, and Duncan subsequently claimed a ‘victory for informed European policy-making’ in a statement, saying he was ‘glad that the pressure exerted on the commission has resulted in a U-turn’. He also suggested the meeting notes could be backed up by a recording, but has not yet responded to a request from Chemistry World to produce the audio.
 
Bertaud, however, insists that nothing has changed with regard to the chief scientific adviser post. While she refuses to say whether Timmermans misspoke or his remarks have been misreported, she explains it has not yet been decided how the commission will handle scientific advice in future. ‘The president values independent scientific advice as a contribution to the policy-making process,’ she says. ‘He has asked Carlos Moedas, the new commissioner for research, science and innovation, to explore options by summer for how to operationalise this in the new commission.’
 
Moedas himself reiterated this in a recent interview, saying he will investigate the different models for independent science in detail, and present a list of options to Juncker by summer this year.
 
Meanwhile, in response to Duncan and Ford’s claims, the current chief scientific adviser Anne Glover has said that even if the post is reinstated, she will still be leaving at the end of this month, and does not intend to work for the commission again.
 

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.